Skip to main content

Menactra FDA Approval History

FDA Approved: Yes (First approved January 14, 2005)
Brand name: Menactra
Generic name: meningococcal conjugate vaccine
Company: Sanofi Pasteur
Treatment for: Meningococcal Disease Prophylaxis

Menactra (meningococcal conjugate vaccine) is a quadrivalent conjugate vaccine indicated for the prevention of meningococcal disease.

Development timeline for Menactra

DateArticle
Apr 25, 2011Approval FDA Approves Menactra to Prevent Meningococcal Disease in Infants and Toddlers
Jan 17, 2005Approval Menactra Sanofi Pasteur - Treatment for Protection Against Meningococcal Disease
Sep 22, 2004Advisory Panel Recommends FDA Licensure of Aventis' Menactra Vaccine for Protection Against Meningococcal Disease

See also

Menactra (meningococcal conjugate vaccine) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer